Zacks Investment Research lowered shares of Quotient (NASDAQ:QTNT) from a hold rating to a sell rating in a report issued on Wednesday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Several other equities analysts have also commented on QTNT. BTIG Research reissued a buy rating and set a $10.00 price target on shares of Quotient in a research report on Tuesday, March 27th. BidaskClub raised Quotient from a hold rating to a buy rating in a research report on Friday, March 16th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $11.50.
Quotient (NASDAQ:QTNT) last released its quarterly earnings results on Monday, February 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.08. The company had revenue of $5.86 million for the quarter, compared to analyst estimates of $5.20 million. research analysts expect that Quotient will post -2.07 earnings per share for the current fiscal year.
In other Quotient news, Director Prondzynski Heino Von acquired 12,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of $4.28 per share, for a total transaction of $51,360.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Brian Mcdonough acquired 10,000 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were acquired at an average price of $3.87 per share, for a total transaction of $38,700.00. Following the completion of the acquisition, the director now directly owns 47,747 shares in the company, valued at $184,780.89. The disclosure for this purchase can be found here. Insiders own 29.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of QTNT. Perceptive Advisors LLC increased its holdings in Quotient by 61.9% during the 4th quarter. Perceptive Advisors LLC now owns 6,033,020 shares of the company’s stock worth $29,683,000 after purchasing an additional 2,306,034 shares during the last quarter. Prosight Management LP purchased a new stake in Quotient during the 4th quarter worth approximately $4,616,000. Clearbridge LLC increased its holdings in Quotient by 53.2% during the 4th quarter. Clearbridge LLC now owns 2,562,084 shares of the company’s stock worth $12,682,000 after purchasing an additional 890,050 shares during the last quarter. Hudson Bay Capital Management LP increased its holdings in Quotient by 966.7% during the 4th quarter. Hudson Bay Capital Management LP now owns 480,000 shares of the company’s stock worth $2,376,000 after purchasing an additional 435,000 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Quotient by 106.4% during the 4th quarter. Millennium Management LLC now owns 503,735 shares of the company’s stock worth $2,493,000 after purchasing an additional 259,715 shares during the last quarter. Institutional investors own 63.78% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3338217/quotient-qtnt-downgraded-to-sell-at-zacks-investment-research.html.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.